
Douglas J Veale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8522964/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.5	1,705
3	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
4	Synovial tissue inflammation in early and late osteoarthritis. Annals of the Rheumatic Diseases, 2005, 64, 1263-1267.	0.5	779
5	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 2016, 75, 499-510.	0.5	743
6	A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis and Rheumatism, 2006, 54, 3962-3970.	6.7	632
7	The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography. Arthritis and Rheumatism, 2000, 43, 2762-2770.	6.7	611
8	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.5	609
9	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.5	484
10	Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis and Rheumatism, 2007, 56, 323-333.	6.7	415
11	The pathogenesis of psoriatic arthritis. Lancet, The, 2018, 391, 2273-2284.	6.3	347
12	Hypoxia, oxidative stress and inflammation. Free Radical Biology and Medicine, 2018, 125, 15-24.	1.3	343
13	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the Rheumatic Diseases, 2014, 73, 1012-1019.	0.5	314
14	Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nature Reviews Rheumatology, 2016, 12, 385-397.	3.5	267
15	Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis and Rheumatism, 2002, 46, 2034-2038.	6.7	262
16	Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 893-900.	6.7	230
17	Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nature Medicine, 2017, 23, 938-944.	15.2	223
18	Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Annals of the	0.5	218

Rheumatic Diseases, 2004, 63, 162-169.

#	Article	IF	CITATIONS
19	Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis and Rheumatism, 2002, 46, 366-372.	6.7	214
20	Synovial tissue hypoxia and inflammation in vivo. Annals of the Rheumatic Diseases, 2010, 69, 1389-1395.	0.5	198
21	Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology, 2017, 13, 463-475.	3.5	175
22	Dysregulated bioenergetics: a key regulator of joint inflammation. Annals of the Rheumatic Diseases, 2016, 75, 2192-2200.	0.5	172
23	A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Annals of the Rheumatic Diseases, 2005, 64, 859-864.	0.5	158
24	Angiopoietins, growth factors, and vascular morphology in early arthritis. Journal of Rheumatology, 2003, 30, 260-8.	1.0	157
25	Macrovascular disease and systemic sclerosis. Annals of the Rheumatic Diseases, 2000, 59, 39-43.	0.5	150
26	Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies. Arthritis Research and Therapy, 2009, 11, R113.	1.6	150
27	Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Annals of the Rheumatic Diseases, 2004, 63, 342-347.	0.5	147
28	Macrophages in Synovial Inflammation. Frontiers in Immunology, 2011, 2, 52.	2.2	137
29	Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-lºB–dependent signal transduction pathway. Arthritis and Rheumatism, 2006, 54, 105-114.	6.7	134
30	The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2009, 68, 196-200.	0.5	134
31	Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis and Rheumatism, 2010, 62, 711-721.	6.7	132
32	Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1275-1283.	0.5	125
33	Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Annals of the Rheumatic Diseases, 2016, 75, 311-315.	0.5	117
34	Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 1386-1394.	1.0	114
35	Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells. Journal of Immunology, 2017, 198, 2249-2259.	0.4	113
36	Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. Arthritis and Rheumatism, 1998, 41, 663-669.	6.7	110

#	Article	IF	CITATIONS
37	Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: Relationship to mediators of systemic and local inflammation. Arthritis and Rheumatism, 2003, 48, 3085-3095.	6.7	110
38	Increased prevalence of symptomatic macrovascular disease in systemic sclerosis Annals of the Rheumatic Diseases, 1995, 54, 853-855.	0.5	109
39	Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis and Rheumatism, 2001, 44, 2024-2028.	6.7	109
40	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis and Rheumatism, 2008, 59, 699-705.	6.7	109
41	Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers. Journal of Rheumatology, 2009, 36, 1800-1802.	1.0	107
42	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
43	Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. Journal of the American Academy of Dermatology, 2006, 54, 1003-1012.	0.6	105
44	Hypoxia Activates NF-κB–Dependent Gene Expression Through the Canonical Signaling Pathway. Antioxidants and Redox Signaling, 2009, 11, 2057-2064.	2.5	103
45	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Annals of the Rheumatic Diseases, 2011, 70, 423-427.	0.5	101
46	<scp>JAK</scp> / <scp>STAT</scp> Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1959-1970.	2.9	97
47	Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). European Journal of Internal Medicine, 2013, 24, 597-603.	1.0	93
48	Cellular and molecular perspectives in rheumatoid arthritis. Seminars in Immunopathology, 2017, 39, 343-354.	2.8	93
49	Acute Serum Amyloid A Induces Migration, Angiogenesis, and Inflammation in Synovial Cells In Vitro and in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model. Journal of Immunology, 2010, 184, 6427-6437.	0.4	92
50	Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis. Arthritis and Rheumatism, 2011, 63, 2172-2182.	6.7	89
51	Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Annals of the Rheumatic Diseases, 2010, 69, 1172-1178.	0.5	87
52	Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Annals of the Rheumatic Diseases, 2013, 72, 1080-1088.	0.5	87
53	Ustekinumab for the treatment of refractory giant cell arteritis. Annals of the Rheumatic Diseases, 2016, 75, 1578-1579.	0.5	87
54	Acuteâ€phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis and Rheumatism, 2012, 64, 1035-1045.	6.7	86

#	Article	IF	CITATIONS
55	Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Research and Therapy, 2018, 20, 85.	1.6	83
56	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.5	82
57	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE, 2018, 13, e0192704.	1.1	82
58	Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis and Rheumatism, 2006, 54, 3152-3162.	6.7	80
59	Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. Journal of Rheumatology, 2002, 29, 2371-8.	1.0	79
60	Remission in psoriatic arthritis: is it possible and how can it be predicted?. Arthritis Research and Therapy, 2010, 12, R94.	1.6	77
61	Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell–Mediated Suppression in the Context of Autoimmunity. Journal of Immunology, 2015, 195, 528-540.	0.4	76
62	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research, 2005, 7, R80.	2.0	75
63	What makes psoriatic and rheumatoid arthritis so different?. RMD Open, 2015, 1, e000025-e000025.	1.8	75
64	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
65	True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin Â?. Annals of the Rheumatic Diseases, 2004, 63, 1344-1346.	0.5	74
66	International spondyloarthritis interobserver reliability exercisethe INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. Journal of Rheumatology, 2007, 34, 1740-5.	1.0	74
67	CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression. Journal of Immunology, 2017, 198, 4490-4501.	0.4	73
68	Comparison of interferon γ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2010, 69, 181-185.	0.5	72
69	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensusâ€Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 345-355.	2.9	72
70	Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures. Arthritis Research and Therapy, 2011, 13, R33.	1.6	70
71	Mitochondrial mutagenesis correlates with the local inflammatory environment in arthritis. Annals of the Rheumatic Diseases, 2012, 71, 582-588.	0.5	70
72	Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 95.	1.6	70

#	Article	IF	CITATIONS
73	Notchâ€1 mediates hypoxiaâ€induced angiogenesis in rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 2104-2113.	6.7	69
74	Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. Seminars in Arthritis and Rheumatism, 2018, 48, 523-528.	1.6	69
75	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology, 2019, 58, 197-205.	0.9	68
76	Resolution of TLR2-induced inflammation through manipulation of metabolic pathways in Rheumatoid Arthritis. Scientific Reports, 2017, 7, 43165.	1.6	66
77	Synovial Cytokine and Growth Factor Regulation of MMPs/TIMPs: Implications for Erosions and Angiogenesis in Early Rheumatoid and Psoriatic Arthritis Patients. Annals of the New York Academy of Sciences, 1999, 878, 619-621.	1.8	64
78	The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis. Frontiers in Medicine, 2018, 5, 185.	1.2	64
79	Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Practice and Research in Clinical Rheumatology, 2006, 20, 941-947.	1.4	63
80	Toll-Like Receptor 2 Induced Angiogenesis and Invasion Is Mediated through the Tie2 Signalling Pathway in Rheumatoid Arthritis. PLoS ONE, 2011, 6, e23540.	1.1	62
81	IL-17A Expression Is Localised to Both Mononuclear and Polymorphonuclear Synovial Cell Infiltrates. PLoS ONE, 2011, 6, e24048.	1.1	61
82	OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis and Rheumatism, 1997, 40, 352-357.	6.7	60
83	Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Annals of the Rheumatic Diseases, 1999, 58, 342-349.	0.5	60
84	Determinants of Patientâ€Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. Arthritis Care and Research, 2017, 69, 1606-1611.	1.5	58
85	STAT3 Mediates the Differential Effects of Oncostatin M and TNFα on RA Synovial Fibroblast and Endothelial Cell Function. Frontiers in Immunology, 2019, 10, 2056.	2.2	58
86	Regulation of Inflammation and Angiogenesis in Giant Cell Arteritis by Acuteâ€Phase Serum Amyloid A. Arthritis and Rheumatology, 2015, 67, 2447-2456.	2.9	57
87	Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. Annals of the Rheumatic Diseases, 2016, 75, 1392-1398.	0.5	57
88	International spondyloarthritis interobserver reliability exercisethe INSPIRE study: I. Assessment of spinal measures. Journal of Rheumatology, 2007, 34, 1733-9.	1.0	57
89	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.5	56
90	Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis. Arthritis Research and Therapy, 2011, 13, R121.	1.6	55

#	Article	IF	CITATIONS
91	Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability?. Journal of Leukocyte Biology, 2013, 95, 233-241.	1.5	55
92	Synovial Immunophenotype and Anti–Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2017, 69, 2114-2123.	2.9	54
93	Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Annals of the Rheumatic Diseases, 2007, 66, 778-781.	0.5	53
94	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53
95	Angiogenesis in psoriasis and psoriatic arthritis: Clues to disease pathogenesis. Current Rheumatology Reports, 2005, 7, 325-329.	2.1	52
96	Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis and Rheumatism, 2011, 63, 923-932.	6.7	52
97	Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis. Pharmacoeconomics, 2010, 28, 477-487.	1.7	51
98	Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 153.	1.6	51
99	Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. Annals of the Rheumatic Diseases, 2019, 78, 350-354.	0.5	51
100	Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. British Journal of Dermatology, 1995, 132, 32-38.	1.4	50
101	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.5	50
102	Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. Journal of Rheumatology, 2007, 34, 620-2.	1.0	50
103	A Role for the High-Density Lipoprotein Receptor SR-B1 in Synovial Inflammation via Serum Amyloid-A. American Journal of Pathology, 2010, 176, 1999-2008.	1.9	49
104	Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology, 2013, 52, 1572-1582.	0.9	47
105	Fatigue in psoriatic arthritis–Âa cross-sectional study of 246Âpatients from 13Âcountries. Joint Bone Spine, 2016, 83, 439-443.	0.8	47
106	Early changes in serum type ii collagen biomarkers predict radiographic progression at one year in in inflammatory arthritis patients after biologic therapy. Arthritis and Rheumatism, 2007, 56, 2919-2928.	6.7	45
107	Biomarkers for rheumatoid and psoriatic arthritis. Clinical Immunology, 2015, 161, 2-10.	1.4	45
108	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis and Rheumatism, 2002, 46, 837-839.	6.7	44

#	Article	IF	CITATIONS
109	Interleukinâ€17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement. Arthritis and Rheumatism, 2011, 63, 3263-3273.	6.7	44
110	Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint. JCI Insight, 2020, 5, .	2.3	44
111	Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study. Arthritis Research and Therapy, 2011, 13, R7.	1.6	41
112	Redoxâ€Mediated Angiogenesis in the Hypoxic Joint of Inflammatory Arthritis. Arthritis and Rheumatology, 2014, 66, 3300-3310.	2.9	41
113	Targeting bioenergetics prevents CD4 T cell–mediated activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology, 2020, 59, 2816-2828.	0.9	41
114	Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Annals of the Rheumatic Diseases, 2010, 69, 706-714.	0.5	39
115	Enthesitis in Psoriatic Disease. Dermatology, 2012, 225, 100-109.	0.9	39
116	Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. Annals of the Rheumatic Diseases, 2018, 77, 1815-1824.	0.5	38
117	Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase <scp>III</scp> and Longâ€Term Extension Studies. Arthritis Care and Research, 2019, 71, 1387-1395.	1.5	38
118	Rheumatoid arthritis CD14 ⁺ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease. Clinical and Translational Immunology, 2021, 10, e1237.	1.7	38
119	Orphan nuclear receptor NR4A2 induces synoviocyte proliferation, invasion, and matrix metalloproteinase 13 transcription. Arthritis and Rheumatism, 2012, 64, 2126-2136.	6.7	37
120	Dysregulated miR-125a promotes angiogenesis through enhanced glycolysis. EBioMedicine, 2019, 47, 402-413.	2.7	36
121	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. Journal of Rheumatology, 2019, 46, 996-1005.	1.0	36
122	Serum miRNA Signature in Rheumatoid Arthritis and "At-Risk Individuals― Frontiers in Immunology, 2021, 12, 633201.	2.2	36
123	Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. Journal of Clinical Investigation, 2001, 107, 519-528.	3.9	36
124	Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223Âpatients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine, 2016, 83, 335-340.	0.8	35
125	The relationship between pityriasis rubra pilaris and inflammatory arthritis: Case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. Arthritis and Rheumatism, 1999, 42, 1998-2001.	6.7	33
126	Synovial Tissue Analysis for the Discovery of Diagnostic and Prognostic Biomarkers in Patients with Early Arthritis: Table 1 Journal of Rheumatology, 2011, 38, 2068-2072.	1.0	33

#	Article	IF	CITATIONS
127	Readability and Quality of Online Information on Osteoarthritis: An Objective Analysis With Historic Comparison. Interactive Journal of Medical Research, 2019, 8, e12855.	0.6	33
128	Cell Adhesion Molecules in Rheumatoid Arthritis. Drugs and Aging, 1996, 9, 87-92.	1.3	32
129	Success Rate and Utility of Ultrasound-guided Synovial Biopsies in Clinical Practice. Journal of Rheumatology, 2016, 43, 2113-2119.	1.0	32
130	Pathogenesis of psoriatic arthritis. Clinical and Experimental Dermatology, 2001, 26, 333-337.	0.6	31
131	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter — Determining Validation Requirements. Journal of Rheumatology, 2016, 43, 208-213.	1.0	30
132	Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Research and Therapy, 2021, 23, 25.	1.6	30
133	Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis. JCI Insight, 2018, 3, .	2.3	30
134	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity. American Journal of Pathology, 2013, 183, 1243-1257.	1.9	29
135	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. Arthritis Research and Therapy, 2018, 20, 265.	1.6	29
136	Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 1760-1767.	1.0	29
137	The PD-1:PD-L1 axis in Inflammatory Arthritis. BMC Rheumatology, 2021, 5, 1.	0.6	29
138	Functional characterization of NF-ÂB inhibitor-like protein 1 (NFÂBIL1), a candidate susceptibility gene for rheumatoid arthritis. Human Molecular Genetics, 2007, 16, 3027-3036.	1.4	28
139	Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. Arthritis Research and Therapy, 2013, 15, R221.	1.6	28
140	Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B. Journal of Autoimmunity, 2019, 96, 86-93.	3.0	28
141	Insulinâ€Resistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach. Arthritis and Rheumatology, 2020, 72, 896-902.	2.9	28
142	Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans. PLoS ONE, 2013, 8, e66456.	1.1	27
143	C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11618-11623.	3.3	26
144	A clinically based protein discovery strategy to identify potential biomarkers of response to antiâ€TNFâ€Î± treatment of psoriatic arthritis. Proteomics - Clinical Applications, 2016, 10, 645-662.	0.8	26

#	Article	IF	CITATIONS
145	Periarticular Bone Gain at Proximal Interphalangeal Joints and Changes in Bone Turnover Markers in Response to Tumor Necrosis Factor Inhibitors in Rheumatoid and Psoriatic Arthritis. Journal of Rheumatology, 2013, 40, 653-662.	1.0	25
146	Notchâ€l mediates endothelial cell activation and invasion in psoriasis. Experimental Dermatology, 2014, 23, 113-118.	1.4	23
147	Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Research and Therapy, 2013, 15, 224.	1.6	22
148	Monocyte-Derived Dendritic Cell Differentiation in Inflammatory Arthritis Is Regulated by the JAK/STAT Axis via NADPH Oxidase Regulation. Frontiers in Immunology, 2020, 11, 1406.	2.2	22
149	Synovial tissue analysis in clinical trials. Journal of Rheumatology, 2005, 32, 2481-4.	1.0	21
150	Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications. Nature Reviews Rheumatology, 2022, 18, 398-414.	3.5	21
151	Detection of Mycobacterium tuberculosis Group Organisms in Human and Mouse Joint Tissue by Reverse Transcriptase PCR: Prevalence in Diseased Synovial Tissue Suggests Lack of Specific Association with Rheumatoid Arthritis. Infection and Immunity, 2001, 69, 1821-1831.	1.0	20
152	Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis. Annals of the Rheumatic Diseases, 2007, 66, 1656-1660.	0.5	20
153	Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6Âmonths of TNF inhibitor therapy: a comparative analysis. Clinical Rheumatology, 2015, 34, 1857-1865.	1.0	20
154	ACPA Status Correlates with Differential Immune Profile in Patients with Rheumatoid Arthritis. Cells, 2021, 10, 647.	1.8	20
155	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	0.9	20
156	Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy. Musculoskeletal Care, 2017, 15, 23-35.	0.6	19
157	CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration, and Therapeutic Targeting. Frontiers in Immunology, 2021, 12, 722349.	2.2	19
158	Angiogenesis in Arthritis. Methods in Molecular Medicine, 2007, , 343-357.	0.8	18
159	Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. Clinical and Experimental Rheumatology, 2010, 28, 401-4.	0.4	18
160	A qualitative study of work participation in early rheumatoid arthritis. International Journal of Therapy and Rehabilitation, 2010, 17, 24-33.	0.1	17
161	Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes. Arthritis and Rheumatism, 2012, 64, 3290-3301.	6.7	17
162	Knee joint synovitis: study of correlations and diagnostic performances of ultrasonography compared with histopathology. RMD Open, 2018, 4, e000616.	1.8	17

#	Article	IF	CITATIONS
163	Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 193-205.	0.5	16
164	The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology, 2016, 43, 1268-1277.	1.0	15
165	First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. BMJ Case Reports, 2021, 14, e238851.	0.2	15
166	Distinct stromal and immune cell interactions shape the pathogenesis of rheumatoid and psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 1224-1242.	0.5	15
167	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Openâ€Label Trial. Arthritis and Rheumatology, 2019, 71, 1616-1625.	2.9	14
168	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	0.9	14
169	COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. Rheumatology, 2021, 60, 902-906.	0.9	14
170	Psoriatic Arthritis Management Update - Biotherapeutic Options. Journal of rheumatology Supplement, The, 2009, 83, 65-68.	2.2	13
171	A quality improvement intervention failed to significantly increase pneumococcal and influenza vaccination rates in immunosuppressed inflammatory arthritis patients. Clinical Rheumatology, 2020, 39, 747-754.	1.0	13
172	Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". Journal of Rheumatology, 2006, 33, 552-7.	1.0	13
173	Differential Expression of NK Receptors CD94 and NKG2A by T Cells in Rheumatoid Arthritis Patients in Remission Compared to Active Disease. PLoS ONE, 2011, 6, e27182.	1.1	12
174	Synovial Tissue Biopsy Research. Frontiers in Medicine, 2019, 6, 72.	1.2	12
175	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 1640-1646.	0.5	12
176	How Much Is Fatigue Explained by Standard Clinical Characteristics of Disease Activity in Patients With Inflammatory Arthritis? A Longitudinal Study. Arthritis Care and Research, 2014, 66, 1597-1603.	1.5	11
177	Brief Report: Cenetic Variation of the α ₁ â€Antitrypsin Gene Is Associated With Increased Autoantibody Production in Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 1576-1579.	2.9	11
178	Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. Irish Journal of Medical Science, 2019, 188, 169-172.	0.8	11
179	New therapies and new goals for psoriatic arthritis. Arthritis and Rheumatism, 2011, 63, 874-876.	6.7	10
180	Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function. Frontiers in Immunology, 2021, 12, 672461.	2.2	9

#	ARTICLE	IF	CITATIONS
181	Central Role of Semaphorin 3B in a Serumâ€Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2022, 74, 972-983.	2.9	9
182	Angiogenesis in Arthritis: Methodological and Analytical Details. , 2007, 135, 343-358.		9
183	Management of Spondyloarthropathy. Drugs, 2002, 62, 2349-2359.	4.9	8
184	Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. Rheumatology International, 2010, 30, 1571-1580.	1.5	8
185	Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication. BMC Musculoskeletal Disorders, 2011, 12, 11.	0.8	8
186	A multidisciplinary approach to reproductive healthcare in women with rheumatic disease. Irish Journal of Medical Science, 2020, 189, 237-243.	0.8	8
187	Functionally Mature CD1c+ Dendritic Cells Preferentially Accumulate in the Inflammatory Arthritis Synovium. Frontiers in Immunology, 2021, 12, 745226.	2.2	8
188	Angiogenesis in Inflammatory Arthritis. Israel Medical Association Journal, 2019, 21, 345-352.	0.1	8
189	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. Journal of Clinical Rheumatology, 2015, 21, 349-354.	0.5	7
190	Interleukin-6 does not upregulate pro-inflammatory cytokine expression in an ex vivo model of giant cell arteritis. Rheumatology Advances in Practice, 2019, 3, rkz011.	0.3	7
191	Reproductive health outcomes in women with psoriatic arthritis. Annals of the Rheumatic Diseases, 2019, 78, 850-852.	0.5	7
192	Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis. Clinical Immunology, 2019, 199, 47-51.	1.4	7
193	The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis. Journal of Rheumatology, 2019, 46, 1365-1368.	1.0	7
194	How early should psoriatic arthritis be treated with a TNF-blocker?. Current Opinion in Rheumatology, 2010, 22, 393-396.	2.0	6
195	The Impact of a Revised EQ-5D Population Scoring on Preference-Based Utility Scores in an Inflammatory Arthritis Cohort. Value in Health, 2011, 14, 921-927.	0.1	6
196	Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?. Annals of the Rheumatic Diseases, 2014, 73, 951-953.	0.5	6
197	Migrating Polyarthritis as a Feature of Occult Malignancy: 2 Case Reports and a Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-7.	0.2	6

#	Article	IF	CITATIONS
199	What practical skills do rheumatologists of the future need?. Best Practice and Research in Clinical Rheumatology, 2000, 14, 635-648.	1.4	5
200	Pathways of cell activation in spondyloarthropathies. Current Rheumatology Reports, 2001, 3, 435-442.	2.1	5
201	Clinical images: Infliximab therapy of polyarticular small joint sarcoid arthritis. Arthritis and Rheumatism, 2011, 63, 2030-2030.	6.7	5
202	Performance characteristics and predictors of temporal artery ultrasound for the diagnosis of giant cell arteritis in routine clinical practice in a prospective cohort. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 72-78.	0.4	5
203	Irish Smokers with Rheumatoid Arthritis Suffer More Than Their Nonsmoking Counterparts: Table 1 Journal of Rheumatology, 2010, 37, 1062-1062.	1.0	4
204	Pulmonary Fibrosis in Systemic Sclerosis. Journal of Thoracic Imaging, 2012, 27, 44-50.	0.8	4
205	Next-generation analysis of synovial tissue architecture. Nature Reviews Rheumatology, 2020, 16, 67-68.	3.5	4
206	Psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2002, 16, 523-35.	1.4	4
207	Necrotizing Fasciitis in Patients on Methotrexate Therapy. Journal of Clinical Rheumatology, 2013, 19, 289-291.	O.5	3
208	Response to: †Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis' by Raychaudhuri <i>et al</i> . Annals of the Rheumatic Diseases, 2017, 76, e37-e37.	0.5	3
209	Association of the Rheumatoid Arthritis Severity Variant rs26232 with the Invasive Activity of Synovial Fibroblasts. Cells, 2019, 8, 1300.	1.8	3
210	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 20-27.	1.0	3
211	Case definition of psoriatic arthritis. Lancet, The, 2000, 356, 2095.	6.3	2
212	An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions. Irish Journal of Medical Science, 2009, 178, 497-501.	0.8	2
213	Is Remission a More Realistic Goal in Psoriatic Arthritis?. Therapeutic Advances in Musculoskeletal Disease, 2011, 3, 3-7.	1.2	2
214	The effects of alcohol consumption and its associations with disease activity among 979 patients with inflammatory arthritis. RMD Open, 2021, 7, e001510.	1.8	2
215	Miliary Nodularity in a Patient Receiving TNF Inhibitors Is Not Always Miliary Tuberculosis: Figure 1 Journal of Rheumatology, 2012, 39, 651-652.	1.0	1
216	Key Challenges in Rheumatic and Musculoskeletal Disease Translational Research. EBioMedicine, 2014, 1, 95-96.	2.7	1

#	ARTICLE	IF	CITATIONS
217	Therapeutic targets in psoriatic arthritis. International Journal of Clinical Rheumatology, 2015, 10, 489-499.	0.3	1
218	Enrichment of polyfunctional T cells in PsA synovial tissue. Response to: â€~Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells' by Raychaudhuri et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2019-216814.	0.5	1
219	Arthroscopic Guided Synovial Biopsies. Frontiers in Medicine, 2020, 7, 604582.	1.2	1
220	Targeting GM-CSF in rheumatological conditions: risk of PAP. Lancet Rheumatology, The, 2021, 3, e473.	2.2	1
221	MRI-Based Visualisation and Quantification of Rheumatoid and Psoriatic Arthritis of the Knee. Mathematics and Visualization, 2012, , 45-59.	0.4	1
222	A Topological Approach to Quantitation of Rheumatoid Arthritis. Mathematics and Visualization, 2008, , 27-37.	0.4	1
223	Pregnancy outcomes in women with psoriatic arthritis: comment on the article by Remaeus et al. Arthritis and Rheumatology, 2022, 74, 1720-1720.	2.9	1
224	(i) Medical management of the rheumatoid hand. Orthopaedics and Trauma, 2001, 15, 323-328.	0.3	0
225	Reply. Arthritis and Rheumatism, 2013, 65, 284-285.	6.7	0
226	Dr. Wiland, et al, reply. Journal of Rheumatology, 2017, 44, 259.2-259.	1.0	0
227	Reply. Arthritis and Rheumatology, 2017, 69, 2404-2406.	2.9	0
228	05.02â€Differentiating patient responses in rheumatoid arthritis – systems analysis of key molecular networks. , 2017, , .		0
229	02.33â€Altered bioenergetics, mitochondrial function and pro-inflammatory pathways in ra synovium in response to tofacitinib. , 2017, , .		0
230	01.04â€Enrichment of activated cd141+ dendritic cells in inflammatory arthritis. , 2017, , .		0
231	Knowledge of disease, diagnosis, adherence and impact of research in an Irish cohort of patients with inflammatory arthritis. HRB Open Research, 0, 4, 60.	0.3	0
232	Angiogenesis in Psoriasis and Psoriatic Arthritis. , 2007, , 61-64.		0
233	Introduction to "Synovitis - an inflammation of joints destroying the bone". Swiss Medical Weekly, 2012, 142, w13712.	0.8	0